logo-loader
Proactive logo live
AFC Energy PLC - AFC entering a ‘year of delivery’, says Liberum
What brokers say
AFC entering a ‘year of delivery’, says Liberum

Liberum has reaffirmed its ‘buy’ rating on AFC Energy PLC (AIM:AFC, OTC:AFGYF) as the hydrogen...

5 minutes ago
Big caps

Big tech outperformance coming to an end, says broker

Big Tech firms are likely coming to the end of a trend in which they outperform market...

59 minutes ago
Mid caps

bluebird bio set to outperform pessimistic expectations – broker

bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform...

18 hours, 17 minutes ago
Big caps

Disney able to increase shareholder returns, says broker

Walt Disney Co (NYSE:DIS, ETR:WDP) will be able to ramp up its buyback programs, grow its...

19 hours, 55 minutes ago
Insight

Xalles Holdings nurtures technology innovations for lucrative exits

"Management is doing things right; leadership is doing the right things." Famed business...

21 hours, 52 minutes ago
Psychedelics

Psychedelics stocks fly as FDA recognizes Mind Medicine's LSD drug as...

Psychedelics stocks traded higher on Thursday as investor optimism returned to the sector on the...

3 weeks ago
Insight

Nevis Brands CEO talks opportunity for THC beverage Major in California...

Nevis Brands (CSE:NEVI)' cannabis beverage product Major is now available for purchase in...

1 month ago
Artificial Intelligence

1606 Corp sees growth through strategic partnerships in March

1606 Corp. (OTC:CBDW) said in March it plans to focus on growth through strategic partnerships...

1 month ago
Small caps

Organigram and Aurora Cannabis increasingly attractive as Canopy Growth’s...

Cannabis firms OrganiGram Holdings (TSX-V:OGI, NASDAQ:OGI) and Aurora Cannabis Inc (TSX:ACB,...

1 month, 1 day ago

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 7 minutes ago

Join Proactive

Get ahead of the curve